1] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA. [2] BBS Program, Harvard Medical School, Boston, Massachusetts 02115, USA.
1] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA. [2] BBS Program, Harvard Medical School, Boston, Massachusetts 02115, USA. [3] Department of Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, Massachusetts 02115, USA. [4] Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA.
Nat Rev Cancer. 2015 Aug;15(8):473-83. doi: 10.1038/nrc3971. Epub 2015 Jul 2.
Although it is widely accepted that most cancers exhibit some degree of intratumour heterogeneity, we are far from understanding the dynamics that operate among subpopulations within tumours. There is growing evidence that cancer cells behave as communities, and increasing attention is now being directed towards the cooperative behaviour of subclones that can influence disease progression. As expected, these interactions can add a greater layer of complexity to therapeutic interventions in heterogeneous tumours, often leading to a poor prognosis. In this Review, we highlight studies that demonstrate such interactions in cancer and postulate ways to overcome them with better-designed therapeutic strategies.
虽然人们普遍认为大多数癌症都表现出一定程度的肿瘤内异质性,但我们远未了解肿瘤内亚群之间的动态变化。越来越多的证据表明,癌细胞表现为群落,现在越来越多的注意力集中在亚克隆的合作行为上,这些行为会影响疾病的进展。正如预期的那样,这些相互作用可以为异质性肿瘤中的治疗干预增加更大的复杂性,通常导致预后不良。在这篇综述中,我们强调了表明癌症中存在这些相互作用的研究,并提出了通过更好设计的治疗策略来克服这些相互作用的方法。